Mar 7 |
KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
|
Mar 6 |
KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference
|
Feb 27 |
KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
|
Feb 26 |
KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
|
Feb 20 |
KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat
|
Feb 16 |
KalVista Pharmaceuticals CFO discloses sale of 40,855 shares
|
Feb 16 |
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
|
Feb 15 |
KalVista Is Still Cheap After Phase 3 Hereditary Angioedema Data
|
Feb 15 |
KalVista Pharmaceuticals up 16%, prices $160M offering
|
Feb 15 |
KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants
|